3BBLACKBIO1,440.00

3B Blackbio Dx Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue from Operations70.790.5
Other Income12.315.0
Total Income83.0105.6
Expenses
+ Employee Benefit Expense5.16.2
+ Finance Costs0.10.1
+ Depreciation & Amortisation0.90.9
+ Other Expenses10.310.1
EBITDA35.149.9
EBIT34.249.0
Profit
Pretax Income46.463.9
+ Current Tax10.814.8
+ Deferred Tax1.41.5
Tax Expense12.216.3
Net Income34.247.6
Total Comprehensive Income34.247.6
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit70.7
Gross Margin %100.00
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.